Plasma and Cellular Forms of Fibronectin as Prognostic Markers in Sepsis

Table 4

Baseline pFN and EDA-FN concentrations in the plasma of patients with sepsis in relation to the APACHE II and SOFA score calculated on admission to the ICU.

	pFN (mg/L)		value	EDA-FN (mg/L)		value
	Survivors	Nonsurvivors		Survivors	Nonsurvivors
	137.1 (113.4-156.4)	106.8 (66.4-122.0)	0.031	6.7 (4.0-29.5)	11.0 (6.0-23.6)	0.841
	157.0 (153.5-196.7)	99.8 (62.7-159.4)	0.029	4.2 (3.8-12.6)	5.8 (2.5-23.1)	0.727
	152.3 (113.4-168.2)	93.1 (56.7-133.6)	0.002	7.7 (4.0-29.5)	7.6 (2.9-21.2)	0.584
	138.8 (119.3-154.6)	109.9 (62.7-166.6)	0.410	3.9 (3.5-12.2)	12.6 (2.8-25.6)	0.469

The APACHE II scale: in survivors, 57% of patients had APACHE II ≤20, and 43% had APACHE II >20; in nonsurvivors, the proportions were reversed, i.e., 28% of patients had APACHE II ≤20, and 72% had APACHE II >20 (). The SOFA scale: in survivors, 87% of patients had SOFA ≤12, and 13% had SOFA >12; in nonsurvivors, the proportions were reversed, i.e., 38% of patients had SOFA ≤12, and 62% had SOFA >12 ().